Adicet ADI-001 shows robust tissue trafficking, complete B cell depletion in Phase 1

Adicet Bio, Inc.

Mean exposure of 236,701 CAR T cells per million in lymph node biopsies across all dose levels.
At 1E9 dose, 27-64% of total cellular material in evaluable biopsies, exceeding published autologous alpha-beta CAR T levels.
Complete CD19+ B cell depletion observed in secondary lymphoid tissue concurrent with trafficking and activation.
Data highlight potential best-in-class profile vs. anti-CD20 antibodies that failed to deplete B cells in tissues.
Initial clinical data from autoimmune programs (lupus nephritis, SLE, systemic sclerosis, AAV) expected H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.